# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN
- Date: 2026-07-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Delacroix-Boateng, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Pre-travel visit for a naval deployment to French Guiana and the French Antilles. **S**

## History of present illness

Mr. Le Moyne d'Iberville, now 44, returns for his pre-travel vaccines. The squadron is expected to sail early next year for the French Antilles and French Guiana, with weeks ashore near Cayenne and Kourou and possible river work inland, and he expects to be away for many months. He has had no fever since his malaria treatment four months ago. The PCR drawn at his last malaria review was negative. The forearm abscess healed within ten days; the culture grew methicillin-susceptible Staphylococcus aureus, and he needed no antibiotic. His screening tests from the preventive visit were negative for HIV and hepatitis C, and the hepatitis B panel shows he is not immune and has never been infected. He has no egg or gelatin allergy, no thymus disease, no immune-suppressing illness or treatment, and has never had yellow fever vaccine. **S**

| Element | Detail |
|---|---|
| Destination | French Antilles and French Guiana, many months, partly inland |
| Departure | Early next year |
| Malaria | No fever in four months |
| Screening | HIV and hepatitis C negative; not immune to hepatitis B |
| Vaccine screening | No contraindication to yellow fever vaccine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight loss |
| Integumentary | Negative | Forearm healed; no other skin infections |
| Allergic and immunologic | Negative | No vaccine, egg or gelatin allergy; no immune disorder |

3 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 69.4 kg; BMI 22.7 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Immunizations given today

- Yellow fever vaccine, live, single dose; certificate (ICVP) issued, valid from ten days after vaccination **S**
- Hepatitis A vaccine, adult, dose 1 of 2 **S**
- Typhoid Vi polysaccharide vaccine **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; temperature 36.7 C, blood pressure 124/78, pulse 66, weight 69.4 kg |
| Right forearm | Small healed scar; no redness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pre-travel care for the deployment** (Z71.84). Entry to French Guiana requires proof of yellow fever vaccination, and CDC recommends it for all travelers there; a single dose gives long-lasting protection, and the certificate is valid from ten days after vaccination. He is 44, with no contraindication or precaution. CDC also recommends hepatitis A and hepatitis B vaccines for unvaccinated travelers and typhoid vaccine for long stays. No dengue vaccine is recommended for travelers. **S**
   - Yellow fever vaccine today and the international certificate signed.
   - Hepatitis A vaccine dose 1 today; dose 2 in six to twelve months.
   - Typhoid Vi vaccine today.
   - Hepatitis B vaccine (HepB-CpG) dose 1 today; dose 2 at the pre-departure visit.
   - Malaria chemoprophylaxis, insect protection and food and water advice at the pre-departure visit.
2. **Relapsing P. vivax malaria, after radical cure** (B51.9). No relapse four months after radical cure. **S**
   - Continue the fever action plan.
3. **Right forearm abscess** (L02.413). Healed after drainage alone. **S**
   - No further care.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Yellow fever vaccine: indication, entry requirement, contraindications and precautions | Once, before travel | Completed today | Required for entry to French Guiana; no contraindication; age under 60; dose given and certificate issued |
| Examination | Hepatitis A, hepatitis B and typhoid vaccines | Before travel | Completed today | Hepatitis A dose 1, typhoid Vi and HepB-CpG dose 1 given |
| Examination | Rabies pre-exposure vaccination | Discuss before travel | Not indicated | Dogs with rabies are uncommon in French Guiana; rabies is present in bats. His duties are shipboard and coastal; after discussion he chose not to have it and knows to seek post-exposure care after any bite or scratch |
| Medication safety | Malaria chemoprophylaxis choice | Before travel | Due | To be prescribed at the pre-departure visit |
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | No fever in four months |

## Goal progress

- No further malaria relapse in the six months after radical cure. In progress; target 2026-10-13. **S**
- All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure. In progress; target 2026-10-13. **S**
- Knows to have a malaria test the same day for any fever, during travel and for months after return. Outcome by 2026-03-31: Carries a fever card and explained the plan back correctly. **S**

## Guideline basis

- CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026), Centers for Disease Control and Prevention
- French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026), Centers for Disease Control and Prevention
- The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006), Infectious Diseases Society of America

## Follow-up

- Pre-departure review in about eleven weeks. **S**
- Next scheduled visit 2026-10-13: pre-departure review: no relapse, malaria chemoprophylaxis, vector, food and water precautions, standby treatment, and the plan on return. **S**
